Targeting PD-1/PD-L1 in biliary tract cancer: role and available data
Mahmood, Reem D Graham, Kathryn Gleeson, Jack Hubner, Richard A Valle, Juan W McNamara, Mairead G
Mahmood, Reem D
Graham, Kathryn
Gleeson, Jack
Hubner, Richard A
Valle, Juan W
McNamara, Mairead G
Citations
Altmetric:
Abstract
There is a critical need for novel therapies to treat patients with advanced biliary tract cancer (BTC). This systematic review summarizes the evidence-based knowledge for the potential role of PD-1 and PD-L1 monoclonal antibodies in the treatment of patients with early-stage and advanced BTC. An Embase database search was conducted, identifying 15 eligible phase II/III clinical trials for review. Results from recent phase III trials show a statistically significant overall survival (OS) benefit from the addition of PD-1/PD-L1 inhibitors to chemotherapy in the first-line management of advanced BTC. Future research should concentrate on the discovery of biomarkers to identify patients who would benefit most from these therapies.
Description
Date
2023
Publisher
Collections
Keywords
Type
Article
Citation
Mahmood RD, Graham K, Gleeson J, Hubner RA, Valle JW, McNamara MG. Targeting PD-1/PD-L1 in biliary tract cancer: role and available data. Immunotherapy. 2023 Apr 3. PubMed PMID: 37009698. Epub 2023/04/04. eng.